ストックスクリーナーアプリを入手
1.20
3.23%
-0.04
アフターアワーズ：
1.14
-0.06
-5.00%
前日終値:
$1.24
開ける：
$1.37
24時間の取引高:
18.91M
Relative Volume:
16.03
時価総額：
$21.15M
収益：
-
当期純損益:
$-11.24M
株価収益率:
-1.5758
EPS:
-0.7615
ネットキャッシュフロー:
$-4.79M
1週間 パフォーマンス:
-0.83%
1か月 パフォーマンス:
-13.04%
6か月 パフォーマンス:
-4.76%
1年 パフォーマンス:
+108.70%
1日の値動き範囲:
$1.12
$1.39
1週間の範囲:
$1.12
$1.39
52週間の値動き範囲:
$0.5131
$5.01
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
MIRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.20 | 21.15M | 0 | -11.24M | -4.79M | -0.7615 |
|
LLY
Lilly Eli Co
|
780.67 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
156.01 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
69.17 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
189.28 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
121.90 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Mira Pharmaceuticals Inc (MIRA) 最新ニュース
MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology - Knoxville News Sentinel
MIRA Pharmaceuticals’ ketamine analog accepted for publication By Investing.com - Investing.com Nigeria
Breakthrough Ketamine Alternative Passes Key Scientific Review: Phase 2 Trial Coming - Stock Titan
EON Resources Inc. Announcement - The Oklahoman
MIRA Pharmaceuticals’ Ketamir-2 Published in Pharmacology Journal - TipRanks
Two Sigma Investments LP Buys Shares of 24,317 MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World
Citadel Advisors LLC Makes New $112,000 Investment in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World
60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - USA Today
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Shares Acquired by Northern Trust Corp - Defense World
MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program - El Paso Times
MIRA Pharmaceuticals (MIRA) Sets Sights on Major Advancements | - GuruFocus
MIRA Pharmaceuticals (MIRA) Sets Sights on Major Advancements | MIRA Stock News - GuruFocus
MIRA Pharmaceuticals Joins BIO Convention for Strategic Opportunities - TipRanks
MIRA's Novel Pain Drug Shows Promise: Phase 1 Success Leads to Phase 2 Plans as Acquisition Nears - Stock Titan
MIRA Pharmaceuticals announces clinical progress and acquisition update - Investing.com
MIRA Pharmaceuticals announces clinical progress and acquisition update By Investing.com - Investing.com Nigeria
MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M - MSN
MIRA Pharmaceuticals appoints new CFO - Investing.com Australia
MIRA Pharmaceuticals Appoints New Chief Financial Officer - TipRanks
MIRA Pharmaceuticals appoints new CFO By Investing.com - Investing.com UK
MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong - MSN
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
MIRA Pharmaceuticals (MIRA) Projected to Post Earnings on Monday - Defense World
Why Mira Pharmaceuticals Inc (NASDAQ: MIRA) Is A Great Stock Pick For Momentum Investors - Stocksregister
MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong By Stocktwits - Investing.com India
MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals for $60M - TipRanks
MIRA Pharmaceuticals to acquire SKNY in strategic move - Investing.com
MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review - Corsicana Daily Sun
EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million - Benzinga
Renaissance Technologies LLC Takes Position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World
MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity - The Joplin Globe
MIRA Achieves Positive Safety Results in Neurotoxicity Study | M - GuruFocus
EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study - AOL.com
MIRA Pharmaceuticals reports safe profile for Ketamir-2 - Investing.com
MIRA Pharmaceuticals reports safe profile for Ketamir-2 By Investing.com - Investing.com UK
MIRA Pharmaceuticals Completes Key Neurotoxicity Study for Ketamir-2 - TipRanks
Breakthrough: New Drug Outperforms Ketamine in FDA Brain Safety StudyZero Toxicity Detected - Stock Titan
Pharmaceutical Stock Jumps After Key Trial Findings - MSN
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 14.1% in April - Defense World
Mira Pharmaceuticals Inc [MIRA] moved up 7.08: Why It’s Important - dbtnews.com
Financial Metrics Unveiled: Mira Pharmaceuticals Inc (MIRA)’s Key Ratios in the Spotlight - DWinneX
MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2 - MSN
Mira Pharmaceuticals announces key drug development milestone By Investing.com - Investing.com Canada
Mira Pharmaceuticals announces key drug development milestone - Investing.com Australia
MIRA Pharmaceuticals (MIRA) Advances Ketamir-2 Formulations in P - GuruFocus
Mira Pharmaceuticals Inc (MIRA) 財務データ
収益
当期純利益
現金流量
EPS
Mira Pharmaceuticals Inc (MIRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Aminov Erez | Chief Executive Officer |
Nov 20 '24 |
Sale |
1.27 |
44,590 |
56,629 |
1,061,200 |
2.05%
0.22%
大文字化:
|
ボリューム (24 時間):